Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Nieuw aanknopingspunt behandeling borst- en eierstokkanker
feb 2024 | Borstkanker, Gynaecologische oncologie